Trial reportNature medicine2025
Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial.
Abstract readRandomized Controlled TrialClinical Trial, Phase II
In one paragraph
Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet (London, England) · 2026Trial
- Equitable access to monoclonal antibodies targeting parasites.Trends in parasitology · 2026Review
- New thinking for the next generation of antimalarials.EMBO molecular medicine · 2026Review
- Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens.The Journal of clinical investigation · 2026Article
- Monoclonal antibody CIS43LS sets the bar for long-acting malaria protection.The Journal of clinical investigation · 2026Article
- Quantitative and Clinical Pharmacology Perspectives on Next-Generation Malaria Prevention Using Vaccines and Long-Acting Monoclonal Antibodies.Clinical and translational science · 2026Review
- Anti-malaria antibody engineering broadens recognition motifs and reveals new homotypic interactions that enhance protective breadth.Nature communications · 2026Article
- Long-Acting Antimalarial Drug Delivery Systems for Chemoprophylaxis: Formulation Strategies and Routes of Administration.Pharmaceutical research · 2026Review
- Recent Advances, Bottlenecks, and Future Directions inVaccines · 2026Review
- The Evolving Landscape of Malaria Prevention Strategies: A Review of Recent Developments.Pathogens (Basel, Switzerland) · 2026Review
- Comparative assessment of tissue cross-reactivity and pharmacokinetic half-life of malaria monoclonal antibodies.Frontiers in immunology · 2026Article
- Anti-Malaria Antibody Engineering Broadens Recognition Motifs and Reveals New Homotypic Interactions that Enhance Protective Breadth.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Jeff SkinnerMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research, NIAID, NIH, Rockville, MD, USA.ORCID http://orcid.org/0000-0001-5697-0442
Kassoum KayentaoMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Aissata OngoibaMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Sara A HealyMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research, NIAID, NIH, Rockville, MD, USA.ORCID http://orcid.org/0000-0003-3078-6094
Zonghui HuBiostatistics Research Branch, Division of Clinical Research, NIAID, NIH, Rockville, MD, USA.
Anne C PrestonMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research, NIAID, NIH, Rockville, MD, USA.
Amadou NiangalyMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research, NIAID, NIH, Rockville, MD, USA.
Philipp SchwablDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Hamidou CisseMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research, NIAID, NIH, Rockville, MD, USA.ORCID http://orcid.org/0000-0003-0988-3332
Safiatou DoumboMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Didier DoumtabeMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Abdrahamane TraoreMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Shanping LiMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research, NIAID, NIH, Rockville, MD, USA.
Mary E PetersonMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research, NIAID, NIH, Rockville, MD, USA.
Annette M SeilieDepartment of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA.
Chris ChavturDepartment of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA.
Weston StaubusDepartment of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA.
Ming ChangDepartment of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA.
Katrina KelleyDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Hamadi TraoreMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Adama DjiguibaMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Mamadou KeitaMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Adama OuattaraMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
M'Bouye DoucoureMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Mohamed KeitaMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Djelika DiarraMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Mamadou SyllaMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Dramane DiakiteMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Mamadou KonateMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Siriman TraoreMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Amatigué ZéguiméMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Amagana DoloMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Daniel E NeafseyDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1665-9323
Sean C MurphyDepartment of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2048-0131
Boubacar TraoreMalaria Research and Training Centre, Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Robert A SederCellular Immunology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3133-0849
Peter D CromptonMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research, NIAID, NIH, Rockville, MD, USA. pcrompton@niaid.nih.gov.ORCID http://orcid.org/0000-0001-5629-0412
Funding
Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) INV-052365Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) INV-061041
Abstract
CIS43LS is a long-acting monoclonal antibody specific for the Plasmodium falciparum circumsporozoite protein expressed on sporozoites. We previously reported that CIS43LS is protective against P. falciparum infection as detected by thick blood smear (TBS; primary endpoint) in a phase 2 double-blind randomized trial involving 330 healthy Malian adults receiving placebo or a single intravenous infusion of 10 mg kg
Indexed as
Antibodies, MonoclonalAntibodies, ProtozoanMalaria, FalciparumPlasmodium falciparumSporozoitesAdolescentAdultAntimalarialsDouble-Blind MethodFemaleHumansMaleMiddle AgedProtozoan ProteinsTreatment OutcomeYoung AdultAntibodies, MonoclonalAntibodies, ProtozoanAntimalarialscircumsporozoite protein, ProtozoanProtozoan Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.